The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Open accessAbstract
Regulatory T (Treg) cells suppress abnormal/excessive immune responses to self‐ and nonself‐antigens to maintain immune homeostasis. In tumor immunity, Treg cells are involved in tumor development and progression by inhibiting antitumor immunity. There are several Treg cell immune suppressive mechanisms: inhibition of costimulatory signals by CD80 and CD86 expressed by dendritic cells through cytotoxic T‐lymphocyte antigen‐4, interleukin (IL)‐2 consumption by high‐affinity IL‐2 receptors with high CD25 (IL‐2 receptor α‐chain) expression, secretion of inhibitory cytokines, metabolic modulation of tryptophan and adenosine, and direct killing of effector T cells. Infiltration of Treg cells into the tumor microenvironment (TME) occurs in multiple murine and human tumors. Regulatory T cells are chemoattracted to the TME by chemokine gradients such as CCR4‐CCL17/22, CCR8‐CCL1, CCR10‐CCL28, and CXCR3‐CCL9/10/11. Regulatory T cells are then activated and inhibit antitumor immune responses. A high infiltration by Treg cells is associated with poor survival in various types of cancer. Therefore, strategies to deplete Treg cells and control of Treg cell functions to increase antitumor immune responses are urgently required in the cancer immunotherapy field. Various molecules that are highly expressed by Treg cells, such as immune checkpoint molecules, chemokine receptors, and metabolites, have been targeted by Abs or small molecules, but additional strategies are needed to fine‐tune and optimize for augmenting antitumor effects restricted in the TME while avoiding systemic autoimmunity. Here, we provide a brief synopsis of these cells in cancer and how they can be controlled to achieve therapeutic outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Self-citationBrunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Oral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Gu, J., Zhou, J., Chen, Q., Xu, X., Gao, J., Li, X., Shao, Q., Zhou, B., Zhou, H., Wei, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110986 · Cited by 490
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218363 · Cited by 460
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
Intricacies of TGF-β signaling in Treg and Th17 cell biology
Wang, J., Zhao, X., & Wan, Y. Y. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01036-7 · Cited by 356
Macrophage Polarity and Disease Control
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010144 · Cited by 318
Bacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Liu, Y., He, S., Wang, X.-L., Peng, W., Chen, Q.-Y., Chi, D.-M., Chen, J.-R., Han, B.-W., Lin, G.-W., Li, Y.-Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21043-4 · Cited by 291
Antitumor effects of immunity-enhancing traditional Chinese medicine
Wang, Y., Zhang, Q., Chen, Y., Liang, C.-L., Liu, H., Qiu, F., & Dai, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109570 · Cited by 287
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Habanjar, O., Bingula, R., Decombat, C., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044002 · Cited by 263
Pinato, D. J., Murray, S. M., Forner, A., Kaneko, T., Fessas, P., Toniutto, P., Mínguez, B., Cacciato, V., Avellini, C., Diaz, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003311 · Cited by 228
The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases
Korbecki, J., Bajdak-Rusinek, K., Kupnicka, P., Kapczuk, P., Simińska, D., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073490 · Cited by 161
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
How does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21
“Treg cells constitutively express high levels of CTLA-4 and are attracted to the tumor microenvironment where they help facilitate cancer immune evasion.(27,28) Anti-CTLA-4 antibodies have been shown to decrease both the intratumoural Treg-to-cytotoxic T lymphocyte ratio and the absolute number of tumour-infiltrating…”
BackgroundHuang, M., Celniker, A. F., Chitsazi, R., Dyer, D. P., Jansma, A. L., Kufareva, I., Salanga, C. L., & Handel, T. M. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110736 · Cited by 1
Metadata
- Authors
- Ohue, Y., & Nishikawa, H.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2019-06-18
- Volume
- 110
- Issue
- 7
- Pages
- 2080-2089
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2946663348
- Cited by
- 1,041
- References
- 81
- FWCI
- 33.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.